Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
3 studies found for:    23816960 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Not yet recruiting Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations
Condition: NSCLC
Interventions: Drug: Bevacizumab;   Drug: Erlotinib
2 Recruiting Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Conditions: Lung Neoplasms;   EGFR Gene Mutations
Intervention: Drug: Osimertinib
3 Completed
Has Results
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Conditions: Carcinoma, Non-Small-Cell Lung;   Adenocarcinoma
Interventions: Drug: Pemetrexed;   Drug: BIBW 2992;   Drug: Cisplatin

Study has passed its completion date and status has not been verified in more than two years.